Mereo BioPharma Group

Update in progress

MREO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Mereo BioPharma Group plc is a London-based biopharmaceutical company developing therapies for rare diseases in the UK and US. Its pipeline includes Setrusumab for osteogenesis imperfecta; Alvelestat for AAT-deficiency–related lung disease; Vantictumab for autosomal dominant osteopetrosis type 2; Leflutrozole for hypogonadotropic hypogonadism; Navicixizumab, Etigilimab and Acumapimod in cancer and COPD trials. It licenses Navicixizumab to Feng Biosciences and Leflutrozole to ReproNovo, with AstraZeneca collaboration. Founded 2015.

Company score

Sentiment: -0.06; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive